Ajo LP Lowered Its Johnson & Johnson (JNJ) Stake by $83.90 Million as Share Value Rose

December 12, 2017 - By Peter Erickson

Investors sentiment decreased to 0.83 in Q2 2017. Its down 0.03, from 0.86 in 2017Q1. It worsened, as 50 investors sold JNJ shares while 878 reduced holdings. 105 funds opened positions while 667 raised stakes. 1.73 billion shares or 0.03% less from 1.73 billion shares in 2017Q1 were reported. Oppenheimer & owns 250,761 shares. 1832 Asset Management Ltd Partnership, a Ontario – Canada-based fund reported 3.13 million shares. Bluecrest Capital Management has invested 0.09% in Johnson & Johnson (NYSE:JNJ). 58,570 were accumulated by Foster & Motley. Laffer Investments accumulated 6,360 shares. Cornercap Counsel holds 0.26% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 11,943 shares. Crestwood Advsrs Ltd Liability accumulated 2.38% or 211,673 shares. Moreover, Stoneridge Invest Limited Liability Corp has 3.07% invested in Johnson & Johnson (NYSE:JNJ). New Jersey Better Educational Savings Tru has invested 2.3% in Johnson & Johnson (NYSE:JNJ). Broderick Brian C owns 83,559 shares or 4.09% of their US portfolio. Berson & Corrado Advsrs Ltd Liability Co invested 0.21% in Johnson & Johnson (NYSE:JNJ). Bluefin Trading Ltd owns 0.13% invested in Johnson & Johnson (NYSE:JNJ) for 8,900 shares. North Star Management Corp stated it has 92,470 shares or 1.64% of all its holdings. Finance Counselors holds 1.04% in Johnson & Johnson (NYSE:JNJ) or 158,646 shares. 36,115 are held by Oxbow Limited Liability Co.

Ajo Lp decreased its stake in Johnson & Johnson (JNJ) by 10.65% based on its latest 2017Q2 regulatory filing with the SEC. Ajo Lp sold 635,598 shares as the company’s stock rose 6.85% with the market. The institutional investor held 5.33M shares of the major pharmaceuticals company at the end of 2017Q2, valued at $705.13M, down from 5.97M at the end of the previous reported quarter. Ajo Lp who had been investing in Johnson & Johnson for a number of months, seems to be less bullish one the $379.18B market cap company. The stock increased 0.39% or $0.55 during the last trading session, reaching $141.14. About 4.36 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since December 12, 2016 and is uptrending. It has underperformed by 4.16% the S&P500.

Ajo Lp, which manages about $24.49B and $23.43 billion US Long portfolio, upped its stake in Aercap Hldgs Nv (NYSE:AER) by 328,529 shares to 1.03M shares, valued at $47.87M in 2017Q2, according to the filing. It also increased its holding in Navient Corp (NASDAQ:NAVI) by 1.23 million shares in the quarter, for a total of 1.25M shares, and has risen its stake in Altria Group (NYSE:MO).

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 23. They expect $1.72 earnings per share, up 8.86 % or $0.14 from last year’s $1.58 per share. JNJ’s profit will be $4.62B for 20.51 P/E if the $1.72 EPS becomes a reality. After $1.90 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -9.47 % negative EPS growth.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: Fool.com which released: “Dividend stats on Johnson & Johnson” on December 09, 2017, also Fool.com with their article: “Will 2018 Be Johnson & Johnson’s Best Year Yet?” published on December 04, 2017, Seekingalpha.com published: “Johnson & Johnson (JNJ) Management Presents at Citi Global Healthcare Conference” on December 07, 2017. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Johnson & Johnson: Reliable Dividend Clipper” published on December 08, 2017 as well as Fiercebiotech.com‘s news article titled: “Johnson & Johnson’s JLABS looks east as it lands in Shanghai” with publication date: December 05, 2017.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 13 have Buy rating, 5 Sell and 5 Hold. Therefore 57% are positive. Johnson & Johnson has $165 highest and $90 lowest target. $136.94’s average target is -2.98% below currents $141.14 stock price. Johnson & Johnson had 83 analyst reports since August 7, 2015 according to SRatingsIntel. Jefferies maintained Johnson & Johnson (NYSE:JNJ) rating on Wednesday, October 18. Jefferies has “Buy” rating and $161.0 target. As per Monday, September 25, the company rating was initiated by Citigroup. The rating was maintained by Jefferies on Tuesday, March 15 with “Hold”. The stock has “Buy” rating by Cowen & Co on Friday, October 6. The company was maintained on Tuesday, August 15 by Jefferies. Credit Suisse maintained the shares of JNJ in report on Thursday, October 19 with “Buy” rating. The rating was maintained by S&P Research on Wednesday, October 14 with “Buy”. The stock of Johnson & Johnson (NYSE:JNJ) has “Outperform” rating given on Tuesday, August 25 by Cowen & Co. The company was reinitiated on Monday, October 5 by Piper Jaffray. The rating was maintained by UBS on Wednesday, July 19 with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.